Cramer said he is a believer in Timken and suggested the analysts go pick on companies that are not profitable rather than Timken, which is doing a fabulous job for its shareholders.
In the Lightning Round, Cramer was bullish on
Martin Midstream Partners
Cramer was bearish on
Am I Diversified?
In the "Am I Diversified?" segment, Cramer spoke with callers and responded to tweets sent via Twitter to
to see if investors' portfolios have what it takes for today's markets.
The first portfolio included:
Johnson & Johnson
Cramer advised selling Merck and adding an industrial stock like Eaton.
The second portfolio's top holdings included:
Cramer said that this portfolio was perfectly diversified.
The third portfolio had:
as its top five stocks.
Cramer also blessed this portfolio as diversified.
No Huddle Offense
In his "No Huddle Offense" segment, Cramer reminded viewers that when it comes to the drug stocks, earnings don't matter, pipelines do. That's why a company like Merck can offer to buy $15 billion worth of its own stock, 10% of the company. Merck currently has 35 drugs under development and is confident that its future will be far brighter than where its shares trade today.
The same rule applied to
, which fell 13% on news that one of its biggest pipeline drugs will be delayed, news that sent competitor
shares up 10%.
Still other drug stocks, like
, saw their shares do little after they reported, Why? Because their pipelines just aren't very exciting at the moment.
To watch replays of Cramer's video segments, visit the Mad Money page on CNBC
-- Written by Scott Rutt in Washington, D.C.
To email Scott about this article, click here:
Follow Scott on Twitter
or get updates on Facebook,